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ABSTRACT 
Gastrointestinal stromal tumor (GIST) is the most common human sarcoma. Its incidence is 
around 10-15 per million person-years, translating into 150 new cases each year in Sweden. 
The molecular background for the absolute majority of GIST is characterized by gain-of-
function mutations in KIT or PDGFRA genes, both encode receptor tyrosine kinases, allowing 
for targeted treatment with imatinib. This has revolutionized the treatment of GIST, which is 
inherently radio- and chemotherapy insensitive. However, durable remissions are uncommon 
relating to the development of resistance. 
The overall aim of the thesis was to explore novel and current treatments in GIST, as few 
treatment alternatives exist. 
In paper I, we examined the functional role of DOG1 protein, a diagnostic marker, in GIST. 
The protein is a calcium-activated chloride channel. We determined the expression of DOG1 
and found a difference between imatinib-sensitive and imatinib-resistant cell lines with 
regards to subcellular localization. Electrophysiological registration confirmed the 
modulating ability of the DOG1 activator and inhibitor. Only modest effect was seen on 
proliferation, DOG1 inhibition induced a shift from early apoptotic to late apoptotic cells in 
the imatinib-resistant cell line. 
In paper II, we used a new potent inhibitor (CaCCinh-A01) of DOG1. We confirmed its 
inhibitory effect on chloride currents using patch-clamp technique. The cell viability was 
reduced. Furthermore, colony formation ability was markedly decreased after incubation with 
CaCCinh-A01. CaCCinh-A01 also led to a G1-cell cycle arrest, which was not seen with 
T16inh-A01 treatment. Therefore, paper I and II, confirms that DOG1 could potentially be a 
target for therapy.  
In paper III, we explored the antitumoral effects of a novel polymer-based therapy (PVAC). 
In vitro experiments revealed PVAC potently induced a population of non-viable cells, in a 
non-linear dose-response relationship. In vivo PVAC inhibited tumor growth in 
immunocompetent mice, and an increased CD3+ cell infiltration intratumorally was observed.  
In paper IV, we explored the commonly used tyrosine kinase inhibitors imatinib, sunitinib, 
and nilotinib possible interaction with ATP-binding sites, in which we used murine 
pancreatic β-cells as ATP-sensitive K+ (KATP) channel donors. By using patch-clamp 
technique, we showed that all three tyrosine kinase inhibitors decreased the channel activity. 
Further studies revealed an increased channel activity with imatinib in the presence of ATP 
and ADP. 
In paper V, the aim was to determine the safety and efficacy of intratumorally injected 
allogeneic pro-inflammatory dendritic cells (ilixadencel) in patients with advanced GIST and 
progression on tyrosine kinase inhibitors. The study showed an acceptable safety profile, and 
promising radiological response was observed in two out of six patients. 
To conclude, this translational thesis adds knowledge to new potential targets and novel 
antitumoral strategies, and increases our understanding of current treatment. Lastly, a clinical 
study found encouraging response in some patients and warrants further studies. 
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INTRODUCTION 
 
Gastrointestinal stromal tumors (GIST) can arise anywhere in the gastrointestinal 
tract and is the most common type of sarcoma. Its diagnostic specificity was greatly 
improved two decades ago, with the finding of new diagnostic markers like KIT and 
DOG1. At the same time, pathogenic mutations were identified that not only 
increased diagnostic specificity, but also resulted in the introduction of targeted 
therapies. GIST was the first solid tumor with such treatment and has in many ways 
served as a model system for modern targeted therapies. Despite the success of the 
introduction of targeted treatment, resistance ultimately develops in a majority of 
patients, and durable remissions are rare. New treatment alternatives are, therefore, 
needed to address this clinical problem.  
GASTROINTESTINAL STROMAL TUMORS - GIST 
GIST is part of the group of mesenchymal-derived tumors, referred to as sarcomas. 
Sarcomas constitute approximately 1-2% of all cancer in adults (Mastrangelo et al., 
2012), whereas epithelial tumors are the largest group of tumors. Sarcomas constitute 
a heterogeneous group of tumors, with presently about 60 different types, and new 
types are still identified or re-classified with increasing knowledge (Jo and Fletcher, 
2014). Sarcomas are generally classified as either soft tissue sarcomas, often 
abbreviated as STS, or as skeletal sarcomas. GIST belongs to soft tissue sarcomas. 
With the development of new diagnostic methods, significant advantages in 
differentiating and subclassifying these tumors have been made in the last two 
decades. 
In the mid-1900s, there were difficulties in diagnosing and distinguishing between 
different types of mesenchymal tumors. Mesenchymal-derived tumors were, 
including GIST, collectively termed smooth-muscle neoplasms, and classified, 
depending on cellular morphology, as leiomyoma, leiomyosarcoma, 
leiomyoblastoma, depending on if the lesion was benign, malignant or possessed an 
epithelioid feature, they were even misclassified as nerve sheath tumors or 
schwannomas (Fletcher et al., 2002). The introduction of immunohistochemistry in 
the 1980s did not reveal the typical immunophenotype seen in smooth muscle 
differentiated cells, or Schwannian cells (Mazur and Clark, 1983). Electron 
microscopy examination did not show ultrastructural features of smooth muscle cells, 
such as myofilament, therefore the terminology was changed to gastric stromal 
tumors instead of smooth-muscle neoplasm (Mazur and Clark, 1983). In addition, 
given the appearance of the cells with vacuoles, cell processes and primitive 
junctions rather suggested a possible cell source in the myenteric nervous system. 
Further efforts followed to enable differential diagnosis between GIST, leiomyomas 
and schwannomas. Another protein named CD34 was found to be a marker that 
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served this purpose (Miettinen, Virolainen and Maarit-Sarlomo-Rikala, 1995; van de 
Rijn, Hendrickson and Rouse, 1994). However, it was later found that this marker 
was only present in 60-70% of all GIST (Fletcher et al., 2002).  
In the late 1990s, several key findings were made that facilitated the diagnosis of 
GIST. Firstly, it was found that CD117 (KIT) was highly expressed in GIST and 
enabled improved differentiation between GIST and leiomyomatous tumors and 
schwannoma (Sarlomo-Rikala et al., 1998). This was a shared feature with the 
interstitial cells of Cajal (ICC), which serves as the connection between the 
autonomous nervous system and gut muscle, enabling peristalsis (Huizinga et al., 
1995). The similar expression patterns, including vimentin and CD34, also suggested 
the connection between ICC and GIST (Kindblom et al., 1998; Sircar et al., 1999). 
Additionally, it was shown that KIT-deficient mice lacked functional ICCs and KIT-
inhibition in ICC induced a smooth-muscle differentiation (Torihashi et al., 1999; 
Kitamura and Hirotab, 2004). Collectively, it is today believed that GIST originates 
from ICCs or stem cells that typically differentiate into ICCs.  
The finding of abundant KIT expression in GIST soon led to the discovery that gain-
of-function mutation is a common event in GIST (Hirota et al., 1998), which shortly 
after came to revolutionize the treatment of GIST, as described below in the section 
“Clinical management of GIST”.  
Histopathology  
A diagnosis of GIST is difficult using only a morphological examination alone and 
there are several differential diagnoses that need to be considered. Several markers 
have been identified that aid in the diagnosis of GIST, see Table 1. The key findings 
described above had a profound impact on the diagnosis of GIST and confirmed 
these to be sensitive markers for GIST disease (Kindblom et al., 1998; Hornick and 
Fletcher, 2002; Sarlomo-Rikala et al., 1998). The majority, ~95% of GIST express 
KIT (Miettinen and Lasota, 2013). Gene expression analysis had revealed another 
interesting marker for GIST, which was named “Discovered on GIST-1” (DOG1), 
and found to be positive in ~98% of GIST irrespective of mutational status (West et 
al., 2004). It was shortly thereafter introduced into the diagnostic markers and is still 
used today as a hallmark in the diagnosis of GIST. Interestingly, this protein is also 
expressed at high levels in ICCs (Hwang et al., 2009). Protein kinase C theta, is 
expressed in about 85% of GIST and was found to stain all KIT-negative GIST 
specimens, making it a useful marker in the presence of KIT-negative GIST (Motegi 
et al., 2005), as DOG1 is negative in two-thirds of KIT-negative GIST (Liegl et al., 
2009). KIT (CD117) and DOG1 today serve as the preferred markers in GIST 
diagnostics (Figure 1) and can stain almost 100% of GIST tumors (Novelli et al., 
2010). 
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Target protein Proportion positive in GIST 
DOG1 >95% 
KIT (CD117) >95% 
PKC theta 85% 
CD34 60-70% 
Smooth-muscle actin 30-40% 
S100 5% 
 
Table 1. Protein markers expressed in GISTs. (Fletcher et al., 2002; Miettinen, Virolainen and Maarit-
Sarlomo-Rikala, 1995; Motegi et al., 2005). 
Macroscopically, GISTs are commonly well-circumscribed with a pink or tan cut 
surface, which might exhibit necrosis and cystic degeneration (Corless, 2014). Most 
GIST cases (~70%) exhibit a spindle-cell morphology, which is characterized by 
cells arranged in fascicles or spiral pattern. Cell-borders are difficult to distinguish 
depending on syncytial appearance. Epithelioid-type GIST is observed in around 
20% of GIST, with rounded cells with clear cytoplasm, in contrast to spindle-cell 
with more eosinophilic cytoplasm. The remaining (~10-20%) part is a mixed-type, 
where both spindle-cell and epithelioid can be present in the same tumor (Fletcher et 
al., 2002). With the advent of tyrosine kinase inhibitor treatment, it should be noted 
that the morphology and immunophenotype may change during tyrosine kinase 
inhibitor treatment (Pauwels et al., 2005). 
 
Figure 1. An example of GIST from the stomach with a spindle-shaped morphology. From left to 
right: haematoxylin staining (20X and 40X), immunostaining for CD117 (KIT) and DOG1. The 
mutational screening revealed a KIT exon 11 mutation. 
Epidemiology 
As stated above, GIST is the most common type of sarcoma, contributing to about 
20% of the reported soft tissue sarcomas (Ducimetière et al., 2011; Mastrangelo et 
al., 2012; Yang et al., 2019). In a meta-analysis, of 13,500 GIST patients, the 
incidence was found to be around 10-15 per million per year (Søreide et al., 2016). 
However, reported incidences varied 4-5 folds between reported studies. The 
prevalence of GIST has been estimated to be 130 per million (Nilsson et al., 2005), 
and will likely increase in the future as treatment efficacy improves and GIST 
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patients live longer with the disease. The incidence is also age-dependent. The 
median age at the time of diagnosis is around 65, with the age-adjusted incidence 
being 4-5-fold higher for people aged >50 years compared to <50 years of age (Yan 
et al., 2008).  GISTs show no distinct predilection to either gender, and the 
female:male ratio is around one in most reported series (Søreide et al., 2016). 
Secondary malignancies have been reported in 20% of GIST (Cavnar et al., 2019). 
Pediatric GISTs are uncommon and are typically not associated with KIT or 
PDGFRA mutations (Prakash et al., 2005; Miettinen, Lasota and Sobin, 2005).  
The anatomical distribution of GIST is fairly consistent across different studies. 
Stomach (~55%) and the small intestine (~30%) are the most common, together 
making up the absolute majority of localized GIST. Less frequent locations are 
colorectal (6%, which mostly refers to GIST tumors of the rectum) and esophagus 
(0.7%) (Søreide et al., 2016). The predilection for certain anatomical sites is partly 
related to the mutational status (Corless, Barnett and Heinrich, 2011). It has 
previously been shown that small intestinal GISTs have a worse prognosis (Miettinen 
and Lasota, 2006), but after imatinib was introduced, a recent study showed that 
small intestine location does not affect long-term prognosis (Cavnar et al., 2019). 
Micro-GISTs are tumors of small size (ranging from 1 to 10 mm) that rarely become 
malignant, and are frequently encountered in the general population in up to 30% of 
patients (Corless et al., 2002; Kawanowa et al., 2006; Agaimy et al., 2007; Abraham 
et al., 2007). Micro-GISTs do not express mitotic markers and are frequently 
calcified, implicating tumor progression arrest (Corless, 2014). However, they 
frequently carry similar mutations in KIT, and sometimes also PDGFRA, as larger 
GISTs (Muenst et al., 2011; Rossi et al., 2010; Corless et al., 2002). From this, it has 
been hypothesized that the gain-of-function mutations in KIT and PDGFRA are 
indeed early events in the tumor development but are not sufficient to cause clinically 
overt GIST. 
Clinical presentation and work-up 
GISTs vary in size, with most tumors being larger than 5 cm, and only about 10% are 
less than 2 cm (Søreide et al., 2016). Varying degrees of symptoms occurs; while 75-
80% of the patients are symptomatic at the time of diagnosis/clinical presentation, 
20-25% are asymptomatic and the tumors are found on routine imaging, endoscopy, 
or intraoperatively. The disease might follow an indolent course with just minor 
symptoms such as fatigue, dysphagia, palpable mass, and anemia. However, dramatic 
courses with the patient presenting with massive bleeding or tumor rupture that 
requires emergent surgery also occurs (Etherington and DeMatteo, 2019).  
The Scandinavian Sarcoma Group recommends referral to a sarcoma center for 
tumors that are larger than 5 cm, deep-seated tumors, or metastatic disease. 
Multidisciplinary workup is important and should involve surgeons, oncologists, 
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radiologists and pathologists among others. Generally, the preferred imaging for 
GIST is contrast-enhanced computer tomography (CT) of the abdomen and pelvis for 
staging (Casali et al., 2018). GIST is characterized by a contrast-enhanced, most 
commonly in the periphery, tumor mass that can either be exophytic or endophytic 
appearance. Since GIST are commonly large, it is not unusual with tumors present 
outside the organ from which it originally developed (Levy et al., 2003). Upon 
diagnosis, about 15% of patients present with metastatic disease (Cavnar et al., 
2019), and most common metastatic locations are liver and peritoneum, which 
together account for about 80% of metastases, making imaging of abdomen and 
pelvis plausible in the majority of cases. For rectal GISTs, magnetic resonance 
imaging (MRI) may provide better staging (Casali et al., 2018). 
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Molecular basis of GIST 
The majority of GISTs carry driving mutations in the KIT gene (c-kit, stem cell factor 
receptor), and a subset display mutations in the PDGFRA gene (platelet-derived 
growth-factor receptor alpha) (Hirota et al., 1998; Hirota et al., 2003; Heinrich et al., 
2003). Both genes are located on the long arm of chromosome 4 (Stenman, Eriksson 
and Claesson-Welsh, 1989) and encode proteins that belong to the subfamily of type 
III receptor tyrosine kinases (see Figure 2).   
 
 
 
 
 
 
 
 
 
 
Figure 2.  Structure of the type III receptor tyrosine kinases KIT and PDGFRA, with indication of the 
corresponding commonly mutated exons. Adapted and modified from (Joensuu, Hohenberger and 
Corless, 2013). 
Receptor tyrosine kinases (RTK) share some common features but are different in 
several ways. The extracellular part differs between them to ascertain ligand 
specificity. In KIT and PDGFRA, it consists of five immunoglobulin-like domains 
for ligand recognition. The transmembrane is located in the cell membrane and the 
juxtamembrane domain is in close proximity intracellularly. The intracellular part 
contains two domains, one ATP-binding domain and one activation loop. The exons 
encoding for the different parts of the KIT and PDGFRA receptors are shown in 
Figure 2. Upon ligand binding, RTKs, which are usually present in their monomer 
form, dimerize and undergo autophosphorylation, during which phosphates are added 
on selected tyrosine residues in the dimerized pair of receptors. This, in turn, leads to 
the activation of downstream signaling pathways (Schlessinger and Ullrich, 1992). 
Under physiological conditions, ligand binding of stem cell factor (SCF) to KIT and 
of platelet-derived growth factor (PDGF) to PDGFRA leads to dimerization of the 
receptor and subsequent activation (Blume-Jensen et al., 1991; Yuzawa et al., 2007). 
KIT is usually expressed and essential in the function of hematopoietic stem cells, 
Exon 17 
Exon 13 
Exon 11 
Exon 9 
Exon 18 
Exon 14 
Exon 12 
KIT PDGFRA 
Ligand-binding domain 
Regulation of dimerisation 
Juxatamembrane domain 
Tyrosine kinase domain I 
(ATP-binding pocket) 
Kinase insert 
Tyrosine kinase domain II 
(activativation loop) 
Cell membrane 
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melanocytes, germ cells, mast cells and ICCs (Maeda et al., 1992; Huizinga et al., 
1995; Ashman, 1999; Alexeev and Yoon, 2006). In contrast to the normal function of 
RTKs, mutated KIT/PDGFRA mutants are not affected by the presence of ligands; 
instead they are activated in a ligand-independent way, leading to constitutive 
activation. The KIT-receptor is phosphorylated in its mutated form in GIST 
specimens (Rubin et al., 2001) and can be reset to its non-phosphorylated and thereby 
inactive state by imatinib (Rubin et al., 2001; Tuveson et al., 2001), which disrupt 
downstream signaling of the KIT-pathway.  
A signaling pathway can be defined as a sequence of the interacting molecules – 
from receptor to effector function – that ultimately leads to a cellular response. In 
GIST, key signaling pathways occurring downstream of the driver mutations have 
been identified, all leading to increased cell survival and proliferation. The activated 
pathways include the mitogen-activated protein kinase (MAPK) pathway, the 
phosphatidylinositol-3-kinase (PI-3K)/Akt/mTOR-pathway, and signal transducer 
and activator of transcription-3 (STAT3) pathway (Figure 3) (Duensing et al., 2004; 
Rossi et al., 2006; Corless, 2014; Bauer et al., 2007). Attempts to elucidate the 
relevance of these signaling pathways relevance have been made using biochemical 
inhibition of key targets in these pathways, as it could also be a therapeutic strategy 
in KIT/PDGFRA wild-type GIST. Inhibiting PI-3K leads to a more pronounced effect 
in vitro compared to MAPK inhibition (Bauer et al., 2007). Combination of both PI-
3K and MAPK inhibition leads to increased antitumoral activity, but might be limited 
by toxicity seen in vivo (Bosbach et al., 2017).  
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Figure 3. Major signaling pathways in GIST. KIT or PDGFRA mutation leads to a constitutively 
active receptor, which activates downstream signaling pathways, such as MAPK (RAF/MEK/ERK), 
STAT3, and PI3K/Akt pathways for cell proliferation and survival. ETV1 mediated transcription is 
crucial in GIST, and have been shown to be an important survival factor for GIST. Asterisks denote 
pathways mutated in non-KIT/PDGFRA mutated GIST, which activates similar pathways as 
KIT/PDGFRA mutated GISTs. Succinate dehydrogenase (SDH) is located in the mitochondria, 
consisting of four subunits A-D. SDH-deficiency leads to the accumulation of succinate and inhibition 
of prolyl hydroxylases, leading to stabilization of HIF1A and increase transcription of its target genes, 
such as VEGF and IGF for cell growth and angiogenesis. Adapted and modified from Joensuu 2013 
and Corless 2014.  
Approximately 80-90%, of GISTs have mutations in either KIT or PDGFRA 
(Corless, Barnett and Heinrich, 2011). Most commonly, KIT mutations occur in exon 
11, which is seen in 65% of GISTs. Different types of mutation can occur, but are 
most frequently deletions or indels (Joensuu et al., 2017). Deletion in exon 11 is 
associated with a poorer prognosis compared to other mutations in KIT (Martín et al., 
2005). Exon 11 encodes the juxtamembrane domain, which normally has an auto-
inhibitory function (Figure 2) (Mol et al., 2004). Functionally, it is believed that in 
mutated the juxtamembrane domain, the autoinhibitory function is lost. Less common 
is the exon 9 mutations that occur in about 10% of GISTs (Lux et al., 2000), 
encoding the extracellular domain (Figure 2). Exon 9 encodes a domain that is part of 
ligand-recognition, and mutation in exon 9 is believed to cause conformational 
change similar to that observed when SCF-ligand binds the KIT-receptor (Yuzawa et 
al., 2007). Exon 9 frequently occurs in the small intestine (Table 2), and a higher 
dose of tyrosine kinase inhibition is recommended for exon 9 mutated GISTs (Casali 
et al., 2018). Mutations in exon 13 and 17 encoding the intracellular ATP-binding 
site and activation loop rarely occur, but are more common as secondary mutations 
Nucleus 
Cytoplasm 
Extracellular 
KIT/PDGFRA 
STAT3	
STAT 
signalling 
Transcription 
Cytoplasm 
RAS*	
RAF	
MEK	
ERK	
BRAF*	
ETV1 mediated 
transcription 
PI-3K	
AKT	
mTOR	 S6K	
Protein synthesis, 
cell growth 
PTEN	
Mitochondria 
SDHA/B/C/D* 
[Succinate] 
Prolyl	
hydroxylase	
HIF1A	
HIF1A	IGF	VEGF	
NF1*	
Growth signaling 
Angiogenesis 
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causing tyrosine kinase inhibitor resistance (Table 2). PDGFRA mutations are less 
common and do not occur together with KIT mutations (Heinrich et al., 2003). 
However, the sites of mutation are different, where PDGFRA mutation occurs 
predominantly in exon 14 or 18 (about 8%) encoding the intracellular domain with 
the ATP-binding site or activation loop, exon 18 or 14 (Figure 2) (Corless, Barnett 
and Heinrich, 2011). PDGFRA mutated GISTs most frequently occurs in the stomach 
(Table 2). Tumors with the most common mutation affecting codon 842 in exon 18 
are considered to be imatinib-resistant. (Cassier et al., 2012).  
Genetic aberrations/syndrome Frequency Anatomical sites 
KIT mutation 75-80% 
 Exon 8 Rare Small intestine 
Exon 9  8-10% Small intestine, colon 
Exon 11 65-67% All sites 
Exon 13 1% All sites 
Exon 17 1% All sites 
 
PDGFRA mutation ~10% 
 Exon 12 1% All sites 
Exon 14  Rare Stomach 
Exon 18 (D842V) 6% Stomach, mesentery, omentum 
Exon 18 (non-D842V) 2% All sites 
 
Wild-type (not KIT and PDGFRA) ~15% 
 BRAF V600E 2% 
 SDHA/B/C/D mutations 6% Stomach and small intestine 
HRAS, NRAS, PIK3CAmutations  1% 
 Pediatric/Carney Triad 1% Stomach 
NF1 1% Small intestine 
Table 2. Molecular features, mutation frequency and preferential anatomical site of GISTs. Adapted 
and modified from (Corless, 2014; Corless, Barnett and Heinrich, 2011). 
Around 10-15% of GISTs do not have mutations in KIT or PDGFRA, and have been 
classified as wild-type GIST. Morphologically they are often indistinguishable from 
mutated KIT and PDGFRA GIST (Hostein et al., 2010). Identification of several 
other genetic aberrations has improved our understanding of wild-type GIST. 
Succinate-dehydrogenase (SDH) deficient GISTs are the most common among the 
wild-type GIST (Boikos et al., 2016). SDH deficiency leads to increased 
transcription of hypoxia-inducible factor 1-alpha (HIF1A) regulated genes (Figure 3) 
(Corless, 2014). Pediatric and young adult GISTs are overrepresented in the SDH-
deficiency group (Miettinen et al., 2011), which can be found in the germline, as part 
of Carney-Stratakis syndrome, with germline mutations of SDHB, SDHC or SDHD 
(Stratakis and Carney, 2009). Mutations in neurofibromin 1 (NF1) have been 
described in about 1% of GISTs, and occur at a younger age as part of the NF1 
syndrome and are almost exclusively located in the small intestine with multifocal 
low-risk GIST (Miettinen et al., 2006; Andersson et al., 2005; Gasparotto et al., 
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2017). Finally, the BRAF V600E mutations have also been identified, most 
commonly located in the stomach and with activated MAPK-pathway (Figure 3) 
(Hostein et al., 2010; Agaimy et al., 2009). 
Progression beyond KIT/PDGFRA mutations  
Micro-GISTs have provided a model system to study additional aberrations that lead 
to a progression of the disease. Several pivotal findings have identified alterations 
that occur in a step-wise manner in order for progression to occur. ETV1 is a 
transcription factor that is critical for the survival and development of GIST tumors 
(Chi et al., 2010), which is also stabilized by the MAPK pathway (Figure 3). Dual 
inhibition of KIT and MAPK (which suppress the expression of ETV1) leads to a 
durable response in mice treated with KIT and MAPK inhibition (Ran et al., 2015). 
DNA copy number losses are, the most common being loss of chromosomal region 
14q, which is observed in 60-70% of GIST (El-Rifai et al., 2000). Inactivation of the 
cell cycle regulator and tumor suppressor MYC-associated factor X (MAX), occurs 
in 50% of GISTs and micro-GISTs, and is likely an early event in the progression of 
GIST (Schaefer et al., 2017). The tumor suppressor dystrophin has also been shown 
to be inactivated in over 90% of metastatic GIST tumors, providing evidence for its 
role in metastatic behavior, and likely a late event in progression (Wang et al., 2014). 
It is now believed that the progression after initial KIT/PDGFRA mutations is largely 
due to dysregulated cell cycle genes (Ohshima et al., 2019; Schaefer, Mariño-
Enríquez and Fletcher, 2017; Heinrich et al., 2019).   
Discovered on GIST-1 (DOG1) – role in tumors 
Ion channels are proteins that allow the passage of ions to cross the membrane, both 
between intracellular and extracellular compartments. Signals transduction via ion 
channels is usually fast compared to for example RTK-mediated signaling. Ion 
channels are regulated, or gated, by different means such as ligands, voltage, or 
mechanically. During the 1990s, ion channels were found to regulate several critical 
processes that are hallmarks of cancer. They were shown to be involved in the 
regulation of cellular proliferation, cell cycle, apoptosis, invasiveness and it is now 
well accepted that ion channels are critical in many of the processes needed for 
tumorigenesis, as reviewed in (Prevarskaya, Skryma and Shuba, 2018; Leanza et al., 
2016).  
The DOG1 protein, also known as anoctamin-1 (ANO1) or transmembrane member 
16A (TMEM16A), is an ion channel that is widely expressed in the body. It belongs 
to the group of Ca2+-activated Cl- channels (CaCCs), which regulate several critical 
physiological processes such as fluid secretion, smooth-muscle contraction, gut 
peristalsis and nociception (Ferrera, Caputo and Galietta, 2010; Hartzell, Putzier and 
Arreola, 2005).  
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DOG1 is functionally an ion channel that opens in response to increased intracellular 
Ca2+-concentration ([Ca2+]i), and is voltage-dependent (Paulino et al., 2017; Caputo 
et al., 2008). More recently, it has also been shown that phosphatidylinositol 4,5-
bisphosphate (PIP2) is needed for activation (Tembo et al., 2019). In mice, 
knockdown of DOG1 is lethal already within the first month after birth (Rock, 
Futtner and Harfe, 2008). DOG1 regulates a variety of physiological functions, 
notably gut peristalsis that is mediated by ICCs, the likely cell-of-origin of GIST 
(Hwang et al., 2009; Malysz et al., 2017). 
Emerging evidence suggests that DOG1 is involved in tumor progression in several 
types of cancer (Ji et al., 2018). DOG1 overexpression have been observed in several 
tumors such as gastric cancer (Liu et al., 2015), colon cancer (Sui et al., 2014), lung 
(Jia et al., 2015), head and neck (Duvvuri et al., 2012), among others. The 
mechanism of this is not fully understood, and might be explained by ANO1 (encodes 
DOG1 protein) gene located on the long arm of chromosome 11 (11q13), which is 
frequently amplified in tumors (Wang et al., 2017). Which has spurred an 
investigation into its role in tumorigenesis. Furthermore, DOG1 expression has been 
shown to be a prognostic marker in different cancers (Ruiz et al., 2012; Choi et al., 
2014; Li et al., 2016).  
DOG1 have been shown to be involved in several processes critical for cancer cells 
such as proliferation (Deng et al., 2016), cell cycle progression (Guan et al., 2016), 
migration and invasion (Liu et al., 2012), and also in epithelial-mesenchymal 
transition (EMT) (Shiwarski et al., 2014). Interestingly, DOG1 is associated with a 
protein network linking the cell membrane to the cytoskeleton (Perez-Cornejo et al., 
2012). 
In GIST, knockdown of DOG1 inhibited tumor growth in vivo xenograft model, 
which was cell line-dependent, no significant effect was seen in vitro after 
knockdown or biochemical inhibition (Simon et al., 2013). Intriguingly, the authors 
observed that loss of KIT expression often occurred together with loss of DOG1 
expression, in GIST cell lines. However, KIT signaling was not affected by DOG1 
knockdown in vitro (Simon et al., 2013). DOG1 has not been found to be mutated in 
clinical GIST specimens (Li et al., 2015; Miwa et al., 2008). 
Several signaling pathways have been investigated for the mechanisms of how 
DOG1 contributes to tumor progression. Among others, DOG1 has been found to 
activate EGF-receptor (EGFR, also a RTK) signaling in breast cancer to promote 
tumor progression, and both knockdown and biochemical inhibition of DOG1 
decreased EGFR signaling (Britschgi et al., 2013). Further studies revealed that 
DOG1 directly interacted with EGFR, and lead to increased signaling due to 
interaction with the juxtamembrane domain that regulates EGFR activity (Bill et al., 
2015). This provides evidence that DOG1 can interact directly with RTKs. 
Combinatorial inhibition of DOG1 and EGFR inhibition resulted in improved 
efficacy of growth suppression in vitro (Bill et al., 2015). In head and neck squamous 
cell carcinoma, DOG1 overexpression was correlated to reduced levels of the pro-
apoptotic protein Bim (Godse et al., 2017). Indeed,, imatinib has been shown to up-
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regulate Bim in GIST, which leads to increased imatinib-induced apoptosis in GIST 
(Gordon and Fisher, 2010). This might support the combinatorial treatment with 
DOG1 inhibition and TKI treatment using imatinib. Several DOG1 modulators now 
exist (Namkung, Phuan and Verkman, 2011; De La Fuente et al., 2008), and we 
addressed the role of DOG1 using these modulators in paper I and II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  13 
  
CLINICAL MANAGEMENT OF GIST 
The seminal findings of mutated receptor tyrosine kinases paved the way for targeted 
therapies in GIST, being the first solid tumor with targeted therapy. Historical data 
has reported consistently low response rates to conventional chemotherapies, around 
0-15% (Dematteo et al., 2002). Therefore, when imatinib was introduced in 2002 it 
revolutionized the treatment of GIST and increased the median survival from ~1.5 
years (Nilsson et al., 2005; DeMatteo et al., 2000) to 5 years (Blanke et al., 2008a). 
Treatment challenges now consist of the selection of patients that would benefit from 
neoadjuvant and/or adjuvant treatment, and for how long the treatment should 
continue. Further, the majority of patients develop treatment resistance to tyrosine 
kinase inhibitors (TKI), and major efforts are being undertaken to decide optimal 
management of patients, and the development of new treatment strategies. This issue 
is also addressed in this work in paper I, II, III and in a clinical trial paper V.  
Risk stratification 
Risk stratification of patients is crucial for determining the optimal management of 
patients. Several such systems have been developed, the first was developed in 2002 
consisting of two variables; tumor size and mitotic count (Fletcher et al., 2002), 
which was introduced as the National Institute of Health (NIH) criteria, which was 
then modified to also include tumor site and presence of tumor rupture (Table 3) 
(Joensuu, 2008). The risk categories were divided into very low risk, low risk, 
intermediate and high risk. The modified NIH criteria were validated and particularly 
identified patients at high risk (Rutkowski et al., 2011; Joensuu et al., 2012b). Others 
include Armed Forces Institute of Pathology (AFIP) criteria which includes the 
parameters with different cutoffs in NIH modified criteria but lack tumor rupture 
(Miettinen and Lasota, 2006). Nomograms are also available for risk classification 
(Gold et al., 2009). The different classification system has been shown to be 
somewhat similar in terms of performance (Joensuu et al., 2012b). 
The modified NIH criteria for risk stratification are used at Karolinska University 
Hospital. This risk system is good at identifying high-risk patients, and can be used to 
determine whether the patient should be treated with adjuvant TKI treatment or not. 
The mutational status is not included in the present classification system, but has an 
impact on treatment decisions. 
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Risk groups Size (cm) Mitotic counts Tumor site 10-year RFS 
Very low <2 <5 Any 94.9% 
Low 2.1-5 <5 Any 89.7% 
Intermediate  <5 6-10 Stomach 86.9% 
Intermediate  5.1-10 <5 Stomach 
 High risk >10  Any count Any 36.2% 
High risk Any size >10 Any 
 High risk >5 >5 Any 
 High risk <5 >5 Non-stomach 
 High risk 5.1-10 <5 Non-stomach 
 
Table 3. The National Institute of Health (NIH) modified criteria for risk stratification. The 10-year 
recurrence-free survival (RFS) is based on pooled data from 10 different population-based studies. 
Mitotic counts are per 50 high-power fields (HPF). NIH modified criteria also includes tumor rupture, 
if such is present at diagnosis or intraoperatively, it is classified as High risk, regardless of other 
markers. (Joensuu, Hohenberger and Corless, 2013). 
Surgical management of GIST 
The ultimate goal of GIST surgery is radically removing the tumor while preserving 
as much function as possible. Neoadjuvant imatinib can be used to shrink the tumor 
prior to surgery in order to perform less invasive surgery. Detailed imaging is crucial 
in determining the surgical anatomy. Careful surgery is performed in order to prevent 
intraoperative tumor rupture, which is a known poor prognostic factor (Table 3) 
(McCarter et al., 2012).  
The current treatment of localized GIST is surgery. A pivotal study of imatinib as 
adjuvant therapy found that in the placebo arm, around 70% of patients undergoing 
surgery alone is cured (Dematteo et al., 2009). However, adjuvant treatment with 
imatinib was shown to improve recurrence-free survival (RFS) in localized GIST 
(Dematteo et al., 2009). Surgical margins are important, and the goal of surgery is to 
achieve negative microscopic margins, referred to as R0. Further, the macroscopical 
surgical margins are of prognostic significance and should be considered as well 
(Åhlén et al., 2018). 
If R0 resection is not feasible, neoadjuvant imatinib-treatment has to be considered 
(Figure 4), to allow for tumor shrinkage before surgery, enabling less extensive 
surgery while preserving function. R0-resection was possible in 80% of the GISTs 
operated on following neoadjuvant imatinib-treatment (Rutkowski et al., 2013). The 
timing of surgery is dependent on the maximal tumor shrinkage, which is usually 
around 6-9 months of treatment duration. For this purpose, also mutational status 
analysis is of benefit and is recommended in all localized GISTs (Casali et al., 2018), 
to allow selection of the optimal tyrosine kinase inhibitor and adequate dosing in 
cases less sensitive to imatinib. GISTs rarely metastasize to lymph nodes, therefore 
lymphadenectomy is not recommended. However, SDH-deficient GISTs usually 
have lymph engagement that might warrant lymphadenectomy (Boikos et al., 2016). 
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Figure 4. Schematic overview of the clinical management of GIST, as recommended by the European 
Society of Medical Oncology (ESMO). Abbreviations: IM, imatinib; SU, sunitinib; RE, regorafenib; 
PD, progressive disease; TKI, tyrosine kinase inhibitor. Imatinib is used as first treatment line, 
sunitinib as second line and regorafenib as third line. Adapted and modified from (Casali et al., 2018). 
 
Medical treatment 
The discovery of mutations in genes coding for KIT in the late 1990s and PDGFRA 
at the beginning of 2000s led to the introduction of targeted therapy in GIST. 
However, this treatment was first used as a treatment in chronic myelogenous 
leukemia (CML), since that inhibition of ABL (of the BCR-ABL fusion protein 
present in >95% of CML) that exerted strong antitumoral activity in cell lines 
(Druker et al., 1996), and patients (Druker et al., 2001). Further, this demonstrated 
the feasibility of targeting specific alterations in cancer, thus increasing specificity.  
At this time, gain-of-function mutations in KIT had been identified, sharing the 
molecular properties with ABL by being a tyrosine kinase. In 2000, the first GIST 
patient received imatinib as a treatment. The patient had rapidly progressive GIST 
disease, and demonstrated a dramatical tumor response (Joensuu et al., 2001). The 
U.S. Food and Drug Administration (FDA) approved the treatment in 2002, after a 
pivotal clinical trial, where half of the patients displayed a partial response (Demetri 
et al., 2002). The metabolic response was seen on [18F]fluoro-2-deoxy-D-glucose, or 
FDG,- positron emission tomography (PET) scans (FDG-PET), which has become a 
useful marker for response to imatinib treatment (Van den Abbeele, 2008). Recently 
it was also shown that imatinib decreases glycolytic rates, and changes the tumor 
cells into a more oxidative phosphorylation phenotype, and combining mitochondrial 
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inhibition and imatinib treatment enhances the efficacy of antitumoral effect (Vitiello 
et al., 2018). 
Imatinib can prevent the oncogenic signaling that occurs as a consequence of mutated 
KIT or PDGFRA receptors (Buchdunger et al., 2000). It acts by competitively 
inhibiting ATP from binding to the ATP binding site of the RTK (Figure 2), where 
ATP acts as a phosphate-donor for the kinase (Mol et al., 2004). This is a shared 
mode of action for the TKI described herein, and we describe their possible 
interaction with ATP-binding sites on other proteins paper IV.  
Imatinib in the adjuvant setting 
In the adjuvant setting, only imatinib is approved for usage. The duration of treatment 
has been studied in several studies, where duration has been studied for 1-3 years 
(Casali et al., 2015; Corless et al., 2014; Joensuu et al., 2016). The optimal treatment 
duration has been found to be 3 years, since that increases the overall survival (OS) 
and not only progression-free survival (PFS). Three years adjuvant imatinib is 
therefore recommended in Europe for high risk GIST, whereas intermediate risk 
tumors should be discussed in therapy conference (Casali et al., 2018). The duration 
of treatment likely has an effect on patients’ compliance with the medication, as side 
effects are not uncommon. Studies have evaluated both 3- and 5-years duration of the 
treatment, and imatinib cessation occurred in 26% (Joensuu et al., 2012a) and 49% 
(Raut et al., 2018) of patients, respectively. It also stresses the importance of patient 
education upon initiation of TKI treatment, since many side effects can be managed 
as well as the importance of assessing patients’ side effects throughout treatment. The 
clinical dilemma with side effects during TKI treatment is partly addressed in paper 
IV.  
Tyrosine kinase inhibitors in advanced/metastatic GIST 
Advanced and metastatic GIST represents a major challenge, but has favorable 
outcomes since the introduction of TKI treatment. Historical data on survival using 
chemotherapy regimens was low, around 1.5 years (DeMatteo et al., 2000). Today 
three drugs have been approved by the FDA for treating metastatic GIST. Imatinib, 
as discussed above is the first line treatment, followed by sunitinib as the second line 
treatment, and regorafenib is used as a third line treatment regimen. Mutational 
analysis is crucial since this affects the treatment response, however, heterogeneous 
mutational status is common, and may differ even in the same lesion and at different 
locations (Liegl et al., 2008; Antonescu et al., 2005). 
Imatinib has been shown to control the disease in over 80% of GIST patients of cases 
short term (Demetri et al., 2002). After the pivotal trials of imatinib as a treatment for 
advanced GIST, it was found that 400 mg imatinib once a day was comparable to 400 
mg twice a day (Blanke et al., 2008b; Verweij et al., 2004). Today it is known that 
around 20% with advanced disease treated with imatinib have a survival exceeding 
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10 years (Heinrich et al., 2017; Casali et al., 2017), but the long-term follow up failed 
to identify possible prognostic factors (Casali et al., 2017). A trial investigated 
whether imatinib treatment could be discontinued after three years of stable disease, 
in which two-year PFS was 80% in the continuation group compared to 16% in 
discontinuation group (Le Cesne et al., 2010). This indicates that imatinib cannot 
eradicate all tumor cells, and patients should receive imatinib if it is tolerable. Most 
patients do develop resistance against imatinib within around 18 months (Blanke et 
al., 2008b). The most common cause of resistance is secondary mutations in exons 
encoding the intracellular domains of the receptor (Debiec-Rychter et al., 2005; 
Antonescu et al., 2005), thereby interfering with imatinib’s binding.  
Sunitinib is a TKI with activity against several RTKs such as KIT, PDGFRA, 
VEGFR and FLT-3 (Abrams et al., 2003). In a phase III trial evaluating sunitinib as a 
second-line treatment upon progression using imatinib, it was shown that sunitinib 
prolonged both the progression-free survival from 1.4 to 6.8 months, and overall 
survival (PFS and OS, respectively) (Demetri et al., 2006). Sunitinib was also shown 
to be effective in GIST with KIT mutations in ATP-binding sites (exon 13 and 14, see 
Figure 2) (Heinrich et al., 2008). Long-term follow up of the phase III trial revealed 
no difference in OS, which was attributable to the crossover design in the initial study 
(Demetri et al., 2012). Regorafenib is a TKI with multiple targets, but notably for 
KIT, RAF, BRAF and PDGFRA (von Mehren and Joensuu, 2018). Regorafenib was 
approved as a third-line agent after a pivotal study demonstrating a PFS of 4.8 
months compared to 0.9 in the placebo-arm in patients progressing on imatinib and 
sunitinib (Demetri et al., 2013). 
Other TKIs have been used in trials, but not demonstrated superior benefits compared 
to current lines. As described in the “Molecular Basis of GIST” section, there is a 
theoretical rationale for exploring several types of inhibitors such as ETV1, mTOR 
inhibitors, cell cycle inhibitors, which are investigated in clinical trials 
(clinicaltrials.gov; accessed 2019/11/03). In paper I, II and III, we investigated 
novel compounds for antitumoral activity in GIST in vitro. While paper V, assess the 
safety and efficacy of immunotherapy in GIST.  
Immunotherapy in GIST 
Immunotherapy has established itself as a treatment within modern oncology. After 
seminal studies during the last century, it is now appreciated that the immune system 
is capable of both eliminating tumor cells and promoting tumor growth through what 
is called immunoediting (Schreiber, Old and Smyth, 2011). Most of this evidence 
comes from animal studies. In humans, patients on immunosuppressive medication 
(such as transplanted patients) and acquired immunodeficiency (such as AIDS), 
displays an increased risk of developing certain cancers (Grulich et al., 2007). 
Moreover, it has been shown that immune function and profiles are prognostic factors 
in several different cancer types (Clark et al., 1989; Pagès et al., 2005; Zhang et al., 
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2003), suggesting a role of the immune system in disease control. Several therapies 
have been developed to enhance the immune system function and break the tolerance 
that exists within the tumors.  
In GIST, the immunological profile has been found to skew towards an 
immunosuppressive state, i.e. an immunological tolerance within the 
microenvironment. Immune cells creating an immunosuppressive environment were 
found to be relatively more common than immune cells that can mediate a response 
against the tumors (van Dongen et al., 2010). Mutational status in GIST also affects 
the immunological environment in GIST. PDGFRA being more immunogenic active 
with more cytolytic immune cells that could possibly mediate tumor killing compared 
to KIT mutated GISTs (Vitiello et al., 2019). Certain immune cells such as NK-cells 
and CD3+ T-cells are associated with longer PFS (Rusakiewicz et al., 2013). 
Furthermore, TKI treatment can alter the immunological environment within tumors. 
For example, imatinib treatment can activate T-cells, by increasing the ratio between 
cytotoxic (CD8+ T-cells) and regulatory T-cells and also induce apoptosis in 
regulatory T-cells, by downregulating indoleamine 2,3-dioxygenase (Ido), which is 
an immunosuppressive enzyme (Balachandran et al., 2011). There is a reason to 
believe that immunotherapy might be beneficial. Currently, there are six (including 
paper V) studies evaluating immunotherapeutics in GIST (clinicaltrials.gov accessed 
on 2019-11-01). Immune checkpoint inhibitors (such as PD-1 and CTLA-4 
inhibitors) are the most common, which disrupt the immune checkpoint that activates 
immune cells for the antitumoral response (Pardoll, 2012). Interestingly, one trial is 
evaluating Ido-inhibition combined with imatinib, again emphasizing the role of 
preclinical studies to guide clinical studies.  
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AIMS 
The clinical dilemmas addressed in this thesis work are 1) the few treatment 
alternatives that exist after TKI treatment failure, and 2) side-effect that reduces 
compliance for TKI treatment.   
Specific aims of the described papers: 
Paper I: Determine the functional role of DOG1 in GIST  
Paper II: Explore a more potent DOG1 inhibitor for antitumor effects in GIST  
Paper III: Explore possible antitumoral effects of PVAC  
Paper IV: Determine the effects of commonly used TKIs possible interaction with 
the ATP-binding site of ATP-sensitive potassium channel 
Paper V: Determine the safety and efficacy of intratumorally injected pro-
inflammatory allogeneic dendritic cells in advanced GIST disease  
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MATERIAL AND METHODS 
 
This chapter contains a short description of each method that has been used in this 
thesis work, more detailed descriptions of the methodology are given in the papers.  
CELL LINES FOR IN VITRO EXPERIMENTS 
In paper I, two well-established human GIST cell lines were used: GIST882 
(imatinib-sensitive) and GIST48 (imatinib-resistant). Both of these have been 
validated for authenticity in our research group (Berglund et al., 2013; Berglund et 
al., 2014). In paper II, human GIST cell lines GIST-T1 and GIST882 were used. In 
paper III, GIST-T1, A375 (human melanoma) and B16.F10 (murine melanoma) 
were used. In paper IV, MIN6m9 (murine β-cell) was used as an ATP-sensitive 
potassium channel (KATP) source. Maintenance of cells is described in paper I-IV. 
ANIMAL MODEL 
In paper III, two different mouse strains, C57BL/6J and the athymic nude mice 
Crl:NU(NCr)-FOXn1nu, were used to determine the antitumoral effects of PVAC. 
The study was reviewed and approved by the Ethical Committee (Dnr N37/15).  
PATIENTS IN THE CLINICAL STUDY 
In paper V, six patients were included into a trial examining the safety and efficacy 
of a new advanced therapy medicinal product (ATMP), Ilixadencel. The trial was 
reviewed and approved by both the Ethics committee (Dnr 2015/1619-31) and the 
Medical Product Agency (Läkemedelsverket) (Dnr 5.1 2015/77670). The trial was 
conducted in accordance with the Helsinki declaration.  
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MATERIAL 
Compounds 
DOG1 activator and inhibitors (Paper I and II) 
E-act (3,4,5-Trimethoxy-N-(2-methoxyethyl)-N-(4-phenyl-2-thiazolyl)-benzamide) 
was used as DOG1 activator, and CaCCinh-A01 6-(1,1-Dimethylethyl)-2-[(2-
furanylcarbonyl)amino]-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid 
and T16inh-A01 (2-[(5-Ethyl-1,6-dihydro-4-methyl-6-oxo-2-pyrimidinyl)thio]-N-
[4-(4-methoxyphenyl)-2-thiazolyl]-acetamide) were used as DOG1 inhibitors. All 
compounds were dissolved in dimethyl sulfoxide (DMSO). All compounds were 
purchased from either Sigma-Aldrich (Saint Louis, MO, USA) or Merck (Billerica, 
MA, USA). 
PVAC (Paper III) 
PVAC is a polymeric molecule which consists of a polyvinyl alcohol backbone, with 
carbazate moieties groups at some hydroxyl moieties. The compound PVAC was 
synthesized by Specific Polymers (Castries, France) and dissolved in purified water 
(Milli-Q purification system, Millipore, MA, USA) or culture medium prior to use. 
As controls, we used polyvinyl alcohol (Sigma-Aldrich), which has the same 
molecular weight as the PVAC, and ethyl-carbazate (Sigma-Aldrich), which is a low-
molecular weight carbazate compound. Both of these compounds were dissolved in 
deionized and purified water. 
Tyrosine kinase inhibitors (TKIs) 
Imatinib mesylate was used in paper I and IV, while sunitinib malate and nilotinib 
were used in paper IV. Imatinib mesylate was dissolved in deionized and purified 
water, while sunitinib malate and nilotinib were dissolved in DMSO. Imatinib 
mesylate and nilotinib were a gift from Novartis (Basel, Switzerland). Sunitinib 
malate was purchased from Sigma-Aldrich.  
Ilixadencel 
Ilixadencel is a cell product produced from healthy blood donors according to Good 
Manufacturing Practice. Its production has been described in detail (Karlsson-Parra et 
al., 2018), and was produced at Cancer Center Karolinska (Karolinska University 
Hospital, Sweden) or at BioNTech (Idar-Oberstein, Germany). The product was 
provided by Immunicum AB (Stockholm, Sweden). 
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EXPERIMENTAL METHODS 
Immunocytochemistry, immunofluorescence and 
immunohistochemistry (Paper I and III) 
Immunocytochemistry (ICC) and immunofluorescence (IF) are commonly used 
methods to study the expression and subcellular localization of specific protein on 
single layers of cells, while immunohistochemistry is used to study the expression of 
a specific protein in tissue sections. All these methods are based on the interaction 
between antibodies and antigens. The difference between ICC and IF is the detection 
method; ICC is detected by chromogenic substrate, while the IF is detected by the 
secondary antibody conjugated with a fluorophore. In paper I, ICC was used to 
verify the protein expression of CD117 (KIT) and DOG1 in GIST cell lines, and IF 
was used to determine the subcellular localization of these two proteins. In paper III, 
immunohistochemistry was used to stain CD3 (T-cell co-receptor) and Ki-67 
(proliferation marker). 
Electrophysiology (Paper I, II and IV) 
The patch-clamp technique can be used to study electrophysiological events, and 
allow direct recording of single ion channel currents (Hamill et al., 1981). We have 
used the method to study effect of different modulators on Cl- and K+ currents. 
Different experimental setups can be used (Figure 5), in this thesis whole-cell and 
excised inside-out patches were used.  
In paper I and II, whole-cell currents were measured using optimized solution 
(specified in papers) for the DOG1 channel, the pipette was in direct contact with the 
cell’s cytoplasm (right in Figure 5). And in paper IV, we used inside-out excised 
patches (left in Figure 5) to record single channel currents of KATP channel upon 
exposure to tyrosine kinase inhibitors.  
 
 
 
 
 
 
Figure 5. Different modes of patch-clamp technique used in this thesis work. Cell-attached is the first 
step for both modes, after this pulling part of the cell membrane will yield an inside-out mode, while 
applying negative pressure will yield whole-cell mode recording. 
Pull 
Negative 
pressure 
Inside-out Whole-cell Cell-attached 
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In brief, glass pipettes were made of certain size. For paper I and II, using a robotic 
system, the pipette was inserted into the cells and a seal was achieved that creates an 
isolated measurement system. For paper IV, glass pipettes were pulled and attached 
to the cellular membrane, after which it was quickly drawn away, allowing single-
channel recording.  
Cell proliferation, viability and colony-forming ability (Paper I, II and III) 
Several methods were performed in paper I-III to determine possible antitumoral 
effects of various compounds. Assays based on cellular metabolism have been used 
to measure cytotoxicity, cell viability and proliferation. It is important to remember 
that, in certain settings, metabolic alterations from the drug studied might influence 
the results of these assays.  
WST-1 assay 
The commercially available WST-1 assay was used to assess proliferation in paper I. 
WST-1 is a colorimetric assay that enables measurement of cell proliferation and 
viability. This assay is based on the formation of formazan from tetrazolium salt 
WST-1 that is catalyzed by mitochondrial dehydrogenases, and thus the amount of 
formazan corresponds to the number of viable/metabolically active cells.  
CellTiter-Glo assay 
CellTiter-Glo assay is an ATP-dependent cell lytic luminescence method to assess 
cell viability. It employs a recombinant luciferase that catalyzes the reaction from 
luciferin to oxyluciferin, which is an ATP-dependent reaction that generates a 
luminescent signal for detection. The amount of ATP correlates to the number of 
metabolically active cells in the system. The assay also inhibits enzymes that would 
interfere with ATP-measurement (ATPases). This assay was used in paper I and III. 
Colony formation assay 
Colony formation assay, or clonogenic assay, measures the ability for single cells to 
divide after exposure to different compounds. In order to achieve this, cell suspension 
was diluted to desirable concentration (1,000 cells/well in 12-well plates; for 
reference, 2,500-10,000 cells/well were seeded in 96-well plates, which is 10-fold 
smaller (area) than 12-well plates). Cells were treated with DOG1 inhibitors, and no 
medium change or drugs were added during the 10-14 days incubation period. Cells 
were stained, and colonies were quantified. The assay was performed in paper II. 
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Flow cytometry (Paper I, II and III) 
Flow cytometry is a method that has several applications and is used both in research 
and clinical setting. In this work, single cells were analyzed, but flow cytometry can 
also be used to study particles. The cells travel along with the fluidics system and 
enter through a laser beam. From this, different cellular characteristics can be 
determined, such as size and internal complexity (which generally relates to 
granularity). The laser beam will also excite fluorescent probes present on the 
particles or cells and record the returning emission. The flow cytometer can 
differentiate between many different emission signals simultaneously, allowing for 
the identification of cells based on, for example, protein expression.  
Annexin V/7-AAD or PI (Paper I and III) 
Apoptosis is a highly orchestrated sequence of events that occurs inside the cell, 
which is also called programmed cell death. One of the early events during apoptosis 
is the translocation of phosphatidylserine from the inner to the outer surface of 
plasma membrane, exposing itself to the external cellular environment (Vermes et 
al., 1995).  Annexin V has a very high binding affinity for phosphatidylserine and 
binds to apoptotic cells with exposed phosphatidylserine. Annexin V can be 
conjugated to a fluorochrome, such as phycoerythrin, for detection. 7-
aminoactinomycin D (7-AAD) and propidium iodide (PI) are indirect markers of late 
apoptotic/necrotic cell populations, indicating that cells have permeabilized cell 
membranes. By co-staining annexin V and 7-AAD or PI, we could distinguish early 
and late apoptotic/necrotic cells. This finding also serves as an excellent method to 
validate findings from the cellular viability assays described above. Since the status 
of each cell is recorded separately, it is easy to determine the percentage of cells that 
are affected by a certain treatment 
Cell Cycle analysis (Paper II and III) 
The approach for analyzing cell cycle events varies, and in this study, we used 
univariate analysis of DNA content that was stained with PI (Pozarowski and 
Darzynkiewicz, 2004). The histogram generated yields proportion of cells in each 
phase of the cell cycle (G1, S and G2/M), where x-axis indicates the DNA content 
and y-axis the number of events. In this assay, cells were fixed with ethanol prior to 
PI staining. The staining solution contains RNAse A that prevents the binding of PI 
to RNAs. Fragmented DNA, as an indicator of apoptosis, can also be detected, which 
is referred to as the sub-G1 phase (Riccardi and Nicoletti, 2006).  
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Animal experiments (Paper III) 
The animal experiments were performed by Adlego AB Biomedical, at the Astrid 
Fagreaus Laboratory (Solna, Sweden). The experimental setup was inoculating either 
B16.F10 cells into C57BL/6J and MDA-MB-231 cells into athymic nude mice. After 
the tumor reached a certain volume, mice were randomized into three groups to 
reduce potential confounding factors, to receive low-dose PVAC, high-dose PVAC 
or vehicle intratumorally. The B16.F10 inoculated mice were treated three 
times/week, and the MDA-MB-231 inoculated mice were treated twice/week. Tumor 
size and animal health were tracked over time and animals were euthanized at either 
volume indication or study length. Tumors were excised and sent for 
histopathological evaluation. 
STUDY DESIGN OF THE CLINICAL STUDY (PAPER V) 
The trial in paper V was a single-center trial conducted at Karolinska University 
Hospital, and was designed as an open-label and single-armed phase 1 trial. The 
investigational product was ilixadencel. The main inclusion criteria were progressive, 
while on tyrosine kinase inhibitor treatment, advanced or metastatic GIST disease. 
For detailed inclusion and exclusion criteria, see paper V.  
The trial was registered on www.clinicaltrials.gov, identifier: NCT02686944.  
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RESULTS AND DISCUSSION 
 
PAPER I AND II – DOG1 MODULATION IN GIST 
We looked at the functional consequences of DOG1 modulation, by using biochemical 
inhibition with two inhibitors (T16inh-A01 and CaCCinh-A01) and the activator E-act. The two 
studies were conducted sequentially. Shortly after paper I was completed, a study found a 
novel mechanism that DOG1 channel activity inhibition was not needed for antitumoral 
effects; rather, it was found that DOG1 inhibitors which also degraded the protein were 
necessary for maximum antitumoral effects (Bill et al., 2014). Therefore, we investigated the 
DOG1-degradable CaCCinh-A01 in paper II and compared it to T16inh-A01. 
In paper I, we first confirmed DOG1 expression in GIST48 and GIST882 cells. By 
employing confocal laser scanning microscopy, we showed that subcellular localization of 
DOG1 varied between the two cell lines. In GIST882, DOG1 was predominantly expressed 
on the plasma membrane, whereas in GIST48 DOG1 was expressed in close proximity to the 
cell nuclei. It was reported that the spatial distribution of DOG1 was strictly confined to the 
apical part of epithelial cells in the airway lumen, where it regulates fluid secretion (Scudieri 
et al., 2012), suggesting that a defined DOG1 expression pattern might have functional 
consequences.  
We then assessed the effects on Cl- currents using the patch-clamp technique and whole-cell 
configuration. The modulator E-act activated Cl- currents in the presence of high [Ca2+]i, 
while both T16inh-A01 and CaCCinh-A01 inhibited. At the maximum concentration tested, 
T16inh-A01 (GIST882) inhibited Cl- currents more than CaCCinh-A01 (GIST-T1), which 
might be explained by different cell lines. As for specificity, it should be noted that 
knockdown of DOG1 in GIST-T1 resulted in a decrease of chloride currents by 90-96% 
(Simon et al., 2013), suggesting an important role of DOG1 in regulating Cl- currents across 
cell membrane in GIST. In addition, we observed increased channel activity in the presence 
of high [Ca2+]i, supporting that DOG1 is a Ca2+-activated Cl- channel. 
To explore the functional consequences of DOG1 modulation, GIST48 and GIST882 cells 
were treated with E-act or T16inh-A01, and assessed for proliferation rates at different time 
points (paper I). Even though there were significant changes upon the treatment, the absolute 
numbers were low compared to control. We, therefore, interpreted the effect on proliferation 
as minor. In paper II, CaCCinh-A01 and T16inh-01 treated GIST882 and GIST-T1 cells were 
assessed for cell viability at different time points. CaCCinh-A01 reduced cell viability by 
approximately 30% in both GIST-T1 and GIST882 cells. The potency of T16inh-A01 to 
reduce cell viability was different between the cell lines, where it was most potent in GIST-
T1 and less so (~10% reduction) in GIST882. 
In paper I, cells were assessed for the apoptotic markers annexin V (early apoptosis marker) 
and 7-AAD (late apoptotic or necrotic cells), by flow cytometric analysis. In GIST882, only 
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small cell population differences were observed. In GIST48 cells, the population of cells in 
the early apoptotic phase shifted to late apoptotic cells with T16inh-A01 treatment, without 
markedly affecting the double-negative cells.  
In paper II, we also investigated the long-term effect of DOG1 inhibition in GIST-T1 cells 
using colony formation assay. A marked decrease in colony-forming ability was seen, in a 
dose-dependent manner, in CaCCinh-A01 treated cells, while no effect was seen in T16inh-A01 
treated cells.   
Finally, in paper II, cell cycle analysis was performed to investigate whether CaCCinh-A01 
and T16inh-A01 altered the distribution of cells in each cell cycle phase. The effect on the cell 
cycle varied between the DOG1 inhibitors. In both cell lines, CaCCinh-A01 induced a G1-
cell cycle arrest that was dose-dependent, leading to 6-10% increase in cells in G1-phase, 
which is in agreement with reports from epithelial tumors treated with DOG1 inhibitors (Bill 
et al., 2014; Guan et al., 2016). In addition, G1-cell cycle arrest is also seen in DOG1 
knockdown (Deng et al., 2016; Sui et al., 2014). T16inh-A01 did not alter the distribution of 
cells at either concentration.  
Key findings 
o DOG1 localization varies between the cell lines on the subcellular level.  
o DOG1 channel activity is voltage- and Ca2+ dependent, and can be modulated by 
biochemical inhibitors.  
o DOG1 modulation leads to antitumoral effects in GIST. More pronounced effects are 
seen with CaCCinh-A01, leading to both decreased cellular viability, cell cycle arrest 
and decreased the ability to form colonies. The effects of T16inh-A01 was cell-line 
dependent, and decreased cell viability and lead to a shift of early apoptotic into late 
apoptotic cells in imatinib-resistant cell line. 
Significance of the findings 
The outlined effects of DOG1 inhibition in paper II warrant further studies, as it might be a 
suitable target for therapy in GIST. The findings are in agreement with what has been shown 
in epithelial tumors, and that DOG1 degradable-inhibitors (CaCCinh-A01) are more potent 
than DOG1 non-degradable inhibitors (T16inh-A01). To proceed, it is essential to confirm 
these findings in animal models, which have thus far not included biochemical inhibition. 
Evidently, DOG1 interacts with RTKs (Britschgi et al., 2013; Bill et al., 2015), and DOG1 
should be examined for such interactions. The finding that DOG1 localization varies in cell 
lines with different imatinib sensitivity should be further examined, since it is known that 
nuclear KIT receptors exist in imatinib-resistant cell lines (Hsueh et al., 2019). 
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PAPER III – PVAC AS AN ANTITUMORAL AGENT 
In this paper, we evaluated the antitumor effect of a novel compound PVAC in vitro and in 
vivo. In a first step, GIST-T1 cells were used to determine the effect of PVAC on cell 
viability using CellTiter Glo assay. We observed a non-linear dose-response relationship on 
cell viability. This kind of surprising finding led us to investigate whether it was seeding 
density-dependent. Indeed, we showed that high cell density had lower cell viability after 48 
h of PVAC treatment, suggesting that the effect of PVAC was both time and seeding density-
dependent. However, the dose-response relationship was non-linear; this might be due to 
multiple binding sites on the PVAC molecule with an optimal ratio between PVAC and cells 
needed to exert its effect.  
The PVAC polymer molecule consists of polyvinyl alcohol as a backbone with coupled 
carbazate groups. The molar ratio between the two constituents is around 5:1. We therefore 
used polyvinyl alcohol and ethyl-carbazate (carbazate with an ethyl group added to it) as 
negative controls. Our results showed that the two compounds had no effect on cellular 
viability, indicating that PVAC is necessary to achieve the antitumoral effects.  
We further assessed the effect of PVAC on apoptosis using flow cytometric analysis of 
annexin V and 7-AAD or PI-stained cells in A375, B16 and GIST-T1 cell lines. In all three 
cell lines, PVAC treatment potently induced late apoptotic/necrotic cell populations in a non-
linear dose-response relationship. In peripheral mononuclear blood cells, it has been shown 
that lower concentrations of different polymers induce early apoptotic cells (as defined by 
annexin V positivity) more potently than higher doses (Jeong et al., 2017). Morphological 
inspection of A375 cells corresponded to the observations in flow cytometry. We also 
observed cross-linked cell debris, which we believe is an effect of PVAC. Flow cytometric 
analysis of cell cycle in A375 cells was only affected in highest-dose.  
The in vitro results led us to speculate whether PVACs effect was similar to that of other 
investigated polymer-based agents, with a membrane-disrupting mechanism, which had 
shown that antitumoral activity increased with increasing hydrophobicity were more 
hemolytic (Takahashi et al., 2019). However, we found that PVAC molecule was more 
hydrophilic than hydrophobic, and that this likely does not explain the cellular toxicity seen. 
Moreover, PVAC has been shown to reduce hemolysis in red blood cells (Sellberg, 
Unpublished data 2019), which might suggest a membrane-interaction mechanism. Possibly, 
since the carbazate targets biological electrophiles such as carbonyls, it might be 
hypothesized that reactive carbonyl species (RCS) formed in the cell membrane due to 
oxidative stress (Fritz and Petersen, 2013), might be the target for PVAC and through that 
mechanism target the membrane. However, we were not able to confirm it in the present 
study. 
To determine in vivo efficacy, we inoculated B16.F10 (melanoma) cells into 
immunocompetent mice and MDA-MB-231 (breast cancer) into athymic nude mice, and 
treated the mouse models with low-dose (close to optimum dose in in vitro studies) or high-
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dose (about 20-fold higher) of PVAC. We found a significant inhibition of tumor growth in 
the melanoma mouse model. Furthermore, immunostaining of the excised tumors revealed an 
increase of CD3+ cell infiltration, but no difference in Ki-67 staining. In the breast cancer 
mouse model, no inhibition of tumor growth was observed, however, pathologist evaluation 
reported increased leukocyte infiltration and decreased stromal tissue that could be a 
therapeutic effect. In addition, excised tumors were RNA sequenced and some genes were 
related to the immune system, which will be validated in follow-up studies.  
 
Key findings 
o In vitro PVAC displays a non-linear, seeding- and time-dependent antitumoral effect, 
with effects on cellular viability. PVAC constituents did not exert antitumoral effects 
at relevant concentrations.  
o Tumor growth inhibition occurred in the melanoma mouse model after PVAC 
treatment, with an increased intratumoral CD3+ cell infiltration.  
o PVAC treatment appeared safe in mice, with no obvious toxicity reported.  
 
Significance of findings 
This work characterizes the antitumoral effects of PVAC, a novel antitumoral agent, in GIST 
melanoma and breast cancer cell lines. We see this compound as a potential toolbox, we used 
one structure of PVAC in this study, but it can be modulated in several ways, such as the 
molar ratio of carbazate groups and size of PVAC. We find the increased infiltration of CD3+ 
cells promising. As major efforts are being put in to develop agents that can trigger immune 
response. However, further analysis of these cells is needed to draw any firm conclusion.  
Little is known about using polymers as antitumoral agent, but several possible advantages 
exist in large molecule antitumoral compounds. One of the most notable examples is the 
enhanced retention and permeability effect (EPR), which describes the phenomenon that 
large molecules accumulate within the tumor (Maeda, 2017). This effect has been validated 
using PVA in mice, which were shown to accumulate in tumors in a size-dependent manner 
(Tabata, Murakami and Ikada, 1998). In addition, PVA was used as the backbone in a 
molecule targeting melanoma and neuroblastoma, with promising findings in vitro and in 
vivo findings, where the exact mechanism remained obscure as well (Raffaghello et al., 
2006). Others have, however, demonstrated membrane-disrupting mechanisms (Park et al., 
2018; Takahashi et al., 2019). 
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PAPER IV – DIRECT INTERACTION BETWEEN TYROSINE KINASE 
INHIBITORS AND KATP CHANNEL 
In this work, we investigated the effect of tyrosine kinase inhibitors on the KATP channel, 
since this ion channel also contains an ATP-binding site. MIN6m9 murine pancreatic β-cell 
line was used as a KATP channel source. Imatinib, nilotinib, and sunitinib were the TKI used. 
Concentrations were considered to be biologically relevant, as we previously have 
determined intracellular imatinib concentrations in clinical GIST specimens, which showed 
concentrations around ~10-70 µM (Berglund et al., 2014). 
The inside-out configuration of the patch-clamp technique was used to study the direct effect 
of TKIs on the KATP channel. In this mode, cellular metabolism and other factors are omitted 
to allow the recording of single-channel. To determine the presence of KATP channels in the 
membrane patch, we started the recording by exposing the patch to ATP, a known inhibitor, 
which decreased channel activity as expected. The inhibitory capacity, to achieve 50% 
channel activity inhibition, of imatinib was estimated to be 9.4 µM, as determined by 
exposing the KATP channel to various concentrations ranging from 1-100 µM. We found no 
statistical difference in single KATP channel kinetics when exposed to imatinib compared to 
the control solution. 
Next, we investigated whether sunitinib and nilotinib altered KATP channel activity. All TKIs 
used reduced the KATP channel activity. Sunitinib belongs to type I group of TKI, which binds 
ATP-site as mode of action; whereas imatinib and nilotinib belong to type II TKI, which 
binds both the ATP-binding site as well as an allosteric site adjacent to the ATP binding 
pocket (Liu and Gray, 2006). In large screenings, type II inhibitors are typically, but not 
always, more selective compared to type I. For the specific inhibitors, they were rated as 
(based on selectivity score (defined as inhibited protein kinases divided by tested protein 
kinases) imatinib < nilotinib < sunitinib (Davis et al., 2011). 
To further confirm the direct interaction with KATP channel, we recorded other type of ion 
channels such as large-conductance voltage and Ca2+-activated K-channels (KBK) and small-
conductance K-channels (KSK). Unlike KATP, no effect on the channel activity by TKI was 
observed, indicating that it is an on-target effect interfering with ATP-binding site on KATP 
channel.  
In normal β-cells, it is generally considered that the ratio between ATP and ADP is the main 
determinant for the channel activity; where ATP inhibits channel activity and ADP activates 
it. We, therefore, used an experimental setup where isolated membrane patches were exposed 
to ADP and ATP (ratio 1:1), with subsequent exposure to imatinib. These experiments 
revealed an increase in KATP channel activity upon imatinib exposure. This is likely a finding 
that needs to be further validated using whole-cell mode on patch-clamp, to confirm its 
activating ability.  
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Key findings 
o Tyrosine kinase inhibitors, when exposed alone, directly inhibits KATP channels. 
o In the presence of physiological ratio of ATP and ADP, imatinib increased KATP 
channel activity. 
o No effect was seen on other type of channels, such as KBK and KSK. 
 
Significance of the findings 
KATP is omnipresent in the body and is involved in a wide variety of physiological functions 
and is expressed in pancreatic β-cell, muscle, and heart among others. The finding that TKI 
directly interacts with the KATP channel, might explain some of the side effects seen with 
KATP-interacting drugs such as headaches, gastrointestinal motility problems, fluid retention 
(Jahangir and Terzic, 2005) The used tyrosine kinase inhibitors represent both type I and type 
II inhibitors, which generally have different selectivity for the target. We show that both are 
capable of interacting with the KATP channel. 
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PAPER V – CELL-BASED IMMUNOTHERAPY IN GIST – PHASE 1 TRIAL 
In this trial, the safety and efficacy of ilixadencel administration were evaluated. The general 
inclusion criteria were patients with advanced unresectable or metastatic progressing GIST 
while on second or later line (Figure 4). The decision to include patients was made at a 
multidisciplinary treatment conference.  
Six patients were enrolled in the study and received two doses of ilixadencel; a seventh 
patient was screened but did not meet inclusion criteria related to abnormal hematological 
parameters. The mean age of the included patients was 57 years. The line of treatment was 
second (50%), third (16.7%) or fourth (33.3%). Four of the patients had had metastatic 
disease, and two patients had locally advanced that were deemed unresectable.  
Treatment safety was monitored throughout the study, by both clinical examination and blood 
tests (including cell counts, kidney and liver function tests, endocrine, inflammation). In total, 
19 adverse events occurred during the study, of which six were interpreted as probably or 
possibly caused by ilixadencel. The most common was fever and chills (three reported), 
abdominal pain (two reported), discomfort at the injection site (one reported). Fever and 
chills are interpreted as related to the inflammatory response that occurs. All adverse events 
had resolved before the study end. No clinically significant laboratory abnormalities were 
found to be related to ilixadencel treatment. Since the cells are allogeneic, i.e. from another 
individual (donor) than the recipient, we evaluated alloimmunization. Three patients 
developed donor-specific antibodies indicative of alloimmunization. These findings confirm 
the acceptable safety profile from two earlier trials using ilixadencel (Laurell et al., 2017; 
Rizell et al., 2019).  
The tumor response was evaluated by radiological examination at three-month intervals. The 
criteria used in the study were RECIST 1.1 or Choi criteria. Four patients had progressive 
disease on first follow up after 3 months (one at 2 months due to general health deterioration). 
However, two patients exhibited a partial response 6 months after ilixadencel determined by 
Choi criteria, which is the preferred criteria for evaluating GIST tumors (Benjamin et al., 
2007). The duration of partial response was 3 month and 6 months (ongoing response at the 
end of the study). Using RECIST 1.1 criteria, the best response of stable disease occurred in 
two patients that remained for 9 and 12 months (ongoing at the end of study). The PFS was 
4.0 months.  
 
Key findings 
o Ilixadencel is a safe product in patients with advanced GIST. 
o Promising response in two out of six patients warrants further studies. 
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Significance of the findings 
To our knowledge, this is the first trial of cell-based immunotherapy in GIST. 
Immunotherapeutic treatment of GIST is likely beneficial, since the microenvironment in 
GIST is generally immunosuppressive (Rusakiewicz et al., 2013; van Dongen et al., 2010). 
Concurrent treatment with TKIs have been shown to influence the immune system, and this 
should be further studied and which combination would synergize most with immunotherapy. 
Although limited by the few study participants, the response rate, given that the response rate 
is usually around 10% in second-line and following TKIs (Mei et al., 2018), is encouraging 
for future studies.  
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CONCLUDING REMARKS 
In this translational work, several potential therapeutic targets have been identified, as well as 
increased understanding of current treatments. Furthermore, the safety and efficacy of cell-
based immunotherapy in a clinical setting in GIST have been addressed.  
 
In conclusion: 
• Biochemical inhibition of DOG1 is a potential pharmacological target in GIST, owing 
to its abundance in GIST. Further studies should assess its usefulness in an in vivo 
setting and evaluate side effects that might occur.  
• PVAC shows promising antitumor activity in vitro and in vivo, suggesting a novel 
agent for GIST treatment. The mechanism of action remains to be elucidated in future 
studies, this provides a proof-of-concept that activated polymers can lead to 
antitumoral effects in vitro and in vivo.  
• Tyrosine kinase inhibitor interferes with ATP binding site on a commonly expressed 
ion channel, namely the ATP-sensitive K+ (KATP) channel. This finding adds 
important knowledge about TKIs, and may as well explain some of the side effects 
seen in GIST patients during TKI therapy.  
• Ilixadencel has an acceptable safety profile in patients with advanced GIST, and 
promising results seen in two patients warrant further studies. By using treatment with 
the intention to break the intratumoral tolerance might lead to improved clinical 
outcomes. 
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